BeiO赛图: The "NVIDIA" moment for innovative drug industry

（Source: Biopharma Investment Circle）

On March 30, 2026, Biosymmetry announced that it has reached a platform licensing agreement with Taisho Pharmaceutical Co., Ltd. (abbreviated as “Taisho Pharmaceutical”). Biosymmetry grants Taisho Pharmaceutical the right to use its proprietary RenNano® fully human single heavy-chain antibody (HCAb) discovery platform, to support Taisho Pharmaceutical’s internal new drug R&D projects.

For Biosymmetry, which aims to build a “global innovation drug engine,” this is merely a routine slice within its large licensing network—by the end of 2025, similar licensing and cooperation have already exceeded 350 deals.

As external licensing (BD) has become the most important value mainline in China’s innovative drug industry, the way the capital market evaluates an innovative drug company has gradually formed a highly standardized framework: how many core pipelines the company has, what the key clinical progress looks like, whether the upfront payment and total transaction value of a single deal are sufficiently eye-catching, and so on.

For most Biotech companies whose valuation narratives are centered around a small number of core assets, this logic framework can indeed produce effective analytical results.

However, when facing Biotech companies like Biosymmetry, which deeply integrates cutting-edge technological innovation with business model innovation and therefore has distinct platform attributes, the above analytical framework starts to appear insufficient in explanatory power.

The business reality of Biosymmetry has already gone beyond the boundaries of this rule of thumb.

Compared with traditional Biotech companies, what Biosymmetry provides is an innovation capability supply aimed at the core stages of the innovative drug industry and characterized by industrialization: by means of platformization, scaling, and standardization, it continuously improves the discovery efficiency of innovative antibody molecules, compresses early R&D trial-and-error costs, and increases the global success rate of pharmaceutical companies at the source-of-innovation stage.

This potential to fundamentally change the cost and risk structure of innovative drug discovery from the source means the capital market has reason to step out of the fixed framework of observing traditional Biotech companies and recalibrate Biosymmetry’s long-term commercial value from the perspective of a broader underlying generic platform or infrastructure.

To some extent, Biosymmetry’s niche position in the innovative drug industry is quite similar to Nvidia’s position in the artificial intelligence industry ecosystem.

Providers of key underlying capabilities

In the AI industry chain, Nvidia sits at the upstream end. The company’s core chips it produces essentially provide the most critical underlying compute power for the AI era, enabling downstream enterprises to develop specific AI applications with higher efficiency.

Similarly, in the innovative drug industry chain, Biosymmetry provides downstream innovative drug companies with underlying discovery capabilities to make the next generation of drugs faster, at lower cost, and with a higher success rate.

Biosymmetry focuses on over 1,000 potential druggable targets and, relying on its independently developed RenMice series fully human antibody/TCR mouse platform, continuously carries out large-scale antibody discovery and development.

The company obtains antibody sequences through large-scale immunization. It then validates binding candidates and measures affinity by combining analyses of structure, epitopes, and functional potential. Ultimately, it deposits a preferred antibody molecule library of over one million molecules. Based on vast amounts of real data, together with localized AI and automated experimental platforms, it significantly improves antibody screening efficiency and opens up as a “ready-stock” supplier of antibody innovation to innovative drug companies worldwide, becoming an important source of antibody innovation R&D supply.

This initiative by Biosymmetry gradually transforms the antibody discovery process—which previously relied heavily on individual experience, had lengthy workflows, and suffered efficiency fluctuations—into a standardized industrial system that can be scaled up and continuously iterated.

For innovative drug companies, if they integrate Biosymmetry’s powerful antibody discovery capability into their own R&D processes, it is expected to compress both the time cost and the trial-and-error cost of innovative drug R&D.

In fact, based on the data, more and more innovative drug companies are making such a choice.

According to Biosymmetry’s 2025 annual report disclosure, by the end of 2025, the company had cumulatively signed over 350 drug collaboration/development/licensing/transfer agreements. Of these, the number of newly signed agreements in 2025 exceeded 150, accounting for nearly 43% of the total number of historically accumulated agreements; the expansion trend is extremely evident.

Facing the high trial-and-error costs and very low probability of success in front-end R&D, multinational pharma companies and domestic Biotech firms are accelerating the restructuring of early-stage drug discovery activities, turning to platforms like Biosymmetry that have underlying validation capabilities and purchasing assets with higher certainty.

This also indicates that Biosymmetry’s innovative business model has completed the crucial transition from technical validation to commercial validation and has entered a high-frequency output stage.

Full-stack service capability

Nvidia’s strength in its business model lies not only in the fact that its chips perform at the top level in the industry, but also in the way it packages chips, the software stack, development frameworks, and more into a complete, ecosystem-based service system, becoming a development foundation that downstream customers highly depend on.

Through years of technical accumulation and model exploration, Biosymmetry is also beginning to show a similar kind of character.

Biosymmetry provides innovative drug companies with high-quality source molecules based on a “fully human antibody molecule library.” It develops preclinical evaluation products and services centered on a humanized small mouse library, successfully further integrates antibody drug discovery, preparation and supply of humanized target models, preclinical pharmacology and efficacy evaluation services, gene editing services, and more into a systematic whole. This results in full-stack capabilities that cover global markets, making it one of the very few domestic biotech R&D and platform-type companies that integrate four platforms into one.

After customers enter Biosymmetry’s platform system, they are no longer facing one or two standalone tool-like services, but rather a systematic, highly integrated R&D infrastructure.

In the innovative drug R&D process, customers often place far more emphasis on core metrics such as model consistency, experimental standard consistency, and data comparability than on price sensitivity.

The value of this full-stack integrated system from Biosymmetry lies in successfully integrating multiple previously disconnected stages into a single platform, thereby reducing unnecessary data fragmentation while also lowering communication friction and shortening time losses.

Such a systematic full-stack capability will undoubtedly bring higher customer stickiness and stronger pricing power.

In 2025, Biosymmetry’s model animal revenue was RMB 622 million, up 59.86% year over year, making it the largest-volume business. Pharmacology and efficacy revenue was RMB 352 million, up 75.24% year over year, making it one of the core businesses with the fastest growth.

Currently, the company has cumulatively completed more than 8,600 drug evaluation projects for approximately 1,100 global partners, and has assisted some partners in successfully completing many IND filing initiatives.

The signal conveyed by this set of data is clear: Biosymmetry’s high growth has moved beyond a stage determined by a single occasional standalone event; it is driven by large-scale, standardized, and replicable preclinical R&D infrastructure capabilities.

Benefiting from long-term industry development

One key commercial model feature of Nvidia in the AI wave is that it avoids the extremely costly trial-and-error of directly going into developing specific applications. Instead, by providing underlying compute-power chips, it continuously extracts more certain returns from the industry’s arms race.

In the global innovative drug industrial value chain, Biosymmetry is gradually establishing a highly homogeneous commercial model.

Long-term industry historical data show that clinical development of innovative drugs faces extreme tail risks, and most pipelines that enter clinical trial stages ultimately end in failure.

Biosymmetry’s strategic support point lies in its “one thousand mice, ten thousand antibodies” plan. By conducting exhaustive antibody discovery across more than 1,000 potential drug targets, it builds a ready-stock asset library consisting of million-level fully human antibody sequences.

On this basis, Biosymmetry avoids the capital consumption and failure risk of pushing innovative drug molecules independently into late clinical stages. Instead, it broadly licenses these early assets to downstream innovative drug companies that have advantages in specific subfields. By collecting upfront payments, milestone payments, and royalty-sharing of sales after drug launch, it gradually realizes value monetization.

The biggest advantage brought by a model based on the “one thousand mice, ten thousand antibodies” plan is that it greatly disperses the risk of failure of a single pipeline. And through the sheer volume of targets and the antibody base, it maximizes the likelihood of successfully capturing molecules of effective drugs.

According to 2025 annual report data, the company has cumulatively signed more than 350 drug collaboration and licensing agreements. This dense distribution network means Biosymmetry’s asset earnings are deeply bound to the trial-and-error process across the entire innovative drug industry.

Even if a downstream customer’s pipeline development ends in a setback, as long as there are success cases that fit industry statistical patterns within its large licensing base, the milestone payments and commercialization revenue share contained in those deals are enough to convert into continuous and substantial cash flows.

Building the underlying architecture that strips away single-point risk at the application end and systematically captures the industry’s development upside is the essence of Biosymmetry’s innovative business model.

Every time global pharmaceutical capital chases a new target or new molecule, it may turn into a monetization opportunity for Biosymmetry’s future antibody molecule library. This gives Biosymmetry the chance to reasonably capture the commercial premium belonging to a new drug discovery infrastructure supplier from each stage of the innovative drug industry’s development process.

This is also what makes Biosymmetry most worth watching over the long term: its value does not depend on any single short-term hot spot, but is instead bound to the process of long-term innovative drug R&D itself.

This structure—batch-producing core underlying assets at extremely low marginal cost and continuously enjoying dividends from the industry’s long-term prosperity—sets up the unique value positioning for Biosymmetry.

Conclusion

In the innovative drug industry, Biosymmetry is, with more than a decade of underlying technology accumulation, successfully constructing an industry ecosystem position that is logic-homologous to Nvidia’s: both are providers of their industry’s underlying core capabilities, and both are key entry points into the R&D ecosystem, the common starting point for complex innovation, and certain beneficiaries of the industry’s long-term prosperity.

In the current industry cycle where the global innovative drug industry is experiencing a general decline in R&D returns, Biosymmetry’s ability to secure the front-end validation step and provide downstream with scarce capabilities that offer higher certainty has truly targeted the industry’s prominent pain points.

Of course, Biosymmetry’s current share in the innovative drug market is still nowhere near comparable to Nvidia’s absolute dominance in the global compute power market. But the business model it has already proven—based on full-stack innovative drug R&D infrastructure—has enormous potential to rewrite early-stage drug discovery approaches. It is even more capable of reshaping its long-term corporate value as it traverses industry cycles.

Massive information, precise insights—available in the Sina Finance APP